Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Enterprise Value (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Enterprise Value over the past 12 years, most recently at -$874.7 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$874.7 million for Q4 2025, down 21.89% from a year ago — trailing twelve months through Dec 2025 was -$874.7 million (down 21.89% YoY), and the annual figure for FY2025 was -$874.7 million, down 21.89%.
  • Enterprise Value for Q4 2025 was -$874.7 million at Viridian Therapeutics, Inc.\DE, down from -$490.9 million in the prior quarter.
  • Over the last five years, Enterprise Value for VRDN hit a ceiling of -$109.3 million in Q2 2021 and a floor of -$874.7 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$427.9 million (2022), compared with a mean of -$427.5 million.
  • Biggest five-year swings in Enterprise Value: crashed 610.83% in 2021 and later skyrocketed 34.83% in 2025.
  • Viridian Therapeutics, Inc.\DE's Enterprise Value stood at -$197.0 million in 2021, then tumbled by 115.55% to -$424.6 million in 2022, then dropped by 12.44% to -$477.4 million in 2023, then plummeted by 50.32% to -$717.6 million in 2024, then decreased by 21.89% to -$874.7 million in 2025.
  • The last three reported values for Enterprise Value were -$874.7 million (Q4 2025), -$490.9 million (Q3 2025), and -$563.4 million (Q2 2025) per Business Quant data.